Etanercept for treating axial spondyloarthritis

References

• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563–2574.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet Lond Engl. 2017. Jan 19. pii: S0140-6736(16)31591-4.
   Google Scholar
• Akkoç N, Khan MA. Radiographic axial spondyloarthritis versus ankylosing spondylitis. Clin Exp Rheumatol. 2016;34:S7.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783.
   PubMed Web of Science ®Google Scholar
• Cohen JS. Clinical and laboratory improvement in ankylosing spondylitis after treatment with etanercept: a case report. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2000;6:221–224.
   Google Scholar
• Wendling D, Prati C, Demattei C, et al. Anterior chest wall pain in recent inflammatory back pain suggestive of spondyloarthritis. Data from the DESIR cohort. J Rheumatol. 2013;40:1148–1152.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E. Hip disease in ankylosing spondylitis. Curr Opin Rheumatol. 2013;25:448–454.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–2291.
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–2285.
   PubMed Web of Science ®Google Scholar
• Fernández-Espartero C, de Miguel E, Loza E, et al. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis. 2014;73:1350–1355.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res. 2012;64:905–910.
   PubMed Web of Science ®Google Scholar
• Masson Behar V, Dougados M, Etcheto A, et al. Diagnostic delay in axial spondyloarthritis: a cross-sectional study of 432 patients. Jt Bone Spine Rev Rhum. 2016;84(4):467–471.
   PubMedGoogle Scholar
• Boonen A, Chorus A, Miedema H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis. 2001;60:1033–1039.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Sieper J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. Curr Opin Rheumatol. 2014;26:377–383.
   PubMed Web of Science ®Google Scholar
• Costantino F, Talpin A, Said-Nahal R, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis. 2015;74:689–693.
   PubMed Web of Science ®Google Scholar
• Loll B, Fabian H, Huser H, et al. Increased conformational flexibility of HLA-B*27 subtypes associated with ankylosing spondylitis. Arthritis Rheumatol Hoboken NJ. 2016;68:1172–1182.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Thomas RC, Schett G. Spondyloarthritis: may the force be with you? Ann Rheum Dis. 2014;73:321–323.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73:1186–1189.
   PubMed Web of Science ®Google Scholar
• Eckstein F, Kwoh CK, Link TM, et al. Imaging research results from the osteoarthritis initiative (OAI): a review and lessons learned 10 years after start of enrolment. Ann Rheum Dis. 2014;73:1289–1300.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–1076.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349–1356.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;18(4). CD005468.
   Google Scholar
• Wendling D, Toussirot E. Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother. 2004;5:1497–1507.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Loddenkemper C, et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol. 2010;37:823–828.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368.
   PubMed Web of Science ®Google Scholar
• Creemers MCW, Franssen MJAM, van’t Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64:127–129.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–2654.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388–1398.
   PubMed Web of Science ®Google Scholar
• Larbi A, Viala P, Molinari N, et al. Assessment of MRI abnormalities of the sacroiliac joints and their ability to predict axial spondyloarthritis: a retrospective pilot study on 110 patients. Skeletal Radiol. 2014;43:351–358.
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C, Claudepierre P, et al. Non-radiographic spondyloarthritis: a theoretical concept or a real entity? Jt Bone Spine Rev Rhum. 2012;79:531–533.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Jurik AG, Hermann K-GA, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520–1527.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008;23(1). CD002822.
   Google Scholar
• Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73:1819–1825.
   PubMed Web of Science ®Google Scholar
• Lambert RGW, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007;56:4005–4014.
   PubMed Web of Science ®Google Scholar
• Braun J, Landewé R, Hermann K-GA, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646–1652.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann K-GA, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI resulandomizedrandomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012;71:878–884.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sørensen IJ, Hermann K-GA, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2010;69:1065–1071.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665–670.
   PubMed Web of Science ®Google Scholar
• Davis JC, Van der Heijde DMFM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol. 2005;32:1751–1754.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876–1886.
   PubMed Web of Science ®Google Scholar
• Závada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75:96–102.
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393–1397.
   PubMed Web of Science ®Google Scholar
• Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66:419–421.
   PubMed Web of Science ®Google Scholar
• Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondandomizeduandomizedrandomised controlled trial. Ann Rheum Dis. 2006;65:1147–1153.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005;64:124–126.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548.
   PubMed Web of Science ®Google Scholar
• Akkoc N, Can G, D’Angelo S, et al. Therapies of early, advanced, and late onset forms of axial spondyloarthritis, and the need for treat to target strategies. Curr Rheumatol Rep. 2017;19:8.
   PubMed Web of Science ®Google Scholar
• Browne SM, Al-Rubeai M. Selection methods for high-producing mammalian cell lines. Trends Biotechnol. 2007;25:425–432.
   PubMed Web of Science ®Google Scholar
• Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007;7:35–41.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cooper K, Harris P, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess Winch Engl. 2016;20:1–222.
   Web of Science ®Google Scholar
• Yi S, Kim SE, Park M-K, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs Clin Immunother Biopharm Gene Ther. 2012;26:177–184.
   Google Scholar
• Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, candomizedulticentre study (LOADET study). Rheumatol Oxf Engl. 2011;50:1828–1837.
   PubMed Web of Science ®Google Scholar
• Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230–3236.
   PubMed Web of Science ®Google Scholar
• Davis JC, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346–352.
   PubMed Web of Science ®Google Scholar
• Calin A, Dijkmans BAC, Emery P, et al. Outcandomizedulticentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594–1600.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572–1577.
   PubMed Web of Science ®Google Scholar
• Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70:799–804.
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667–1675.
   PubMed Web of Science ®Google Scholar
• Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63:1543–1551.
   PubMed Web of Science ®Google Scholar
• Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:1926–1928.
   PubMed Web of Science ®Google Scholar
• Giardina AR, Ferrante A, Ciccia F, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1437–1440.
   PubMed Web of Science ®Google Scholar
• Song I-H, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70:590–596.
   PubMed Web of Science ®Google Scholar
• Song I-H, Hermann K-G, Haibel H, et al. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41:2034–2040.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol Hoboken NJ. 2014;66:2091–2102.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Dougados M, van der Heijde D, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis. 2016;75:1328–1335.
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol. 2004;31:531–538.
   PubMed Web of Science ®Google Scholar
• Dougados M, Wood E, Combe B, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 2014;16:481.
   PubMed Web of Science ®Google Scholar
• Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess Winch Engl. 2016;20:1–334,v–vi.
   PubMed Web of Science ®Google Scholar
• Navarro-Compán V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30:993–996.
   PubMed Web of Science ®Google Scholar
• Lee J, Noh J-W, Hwang JW, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29:1149–1154.
   PubMed Web of Science ®Google Scholar
• Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012;39:836–840.
   PubMed Web of Science ®Google Scholar
• Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69:1430–1435.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet Lond Engl. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
   PubMed Web of Science ®Google Scholar
• Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69:226–229.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–1331.
   PubMed Web of Science ®Google Scholar
• Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69:1756–1761.
   PubMed Web of Science ®Google Scholar
• Ai J-W, Zhang S, Ruan Q-L, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42:2229–2237.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15:R67.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005;53:856–863.
   PubMed Web of Science ®Google Scholar
• Carmona L, Gómez-Reino JJ, BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234–240.
   PubMed Web of Science ®Google Scholar
• Lunt M, Watson KD, Dixon WG, et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145–3153.
   PubMed Web of Science ®Google Scholar
• Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60:3180–3189.
   PubMed Web of Science ®Google Scholar
• Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648–653.
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–408.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664–674.
   PubMed Web of Science ®Google Scholar
• Nell-Duxneuner V, Schroeder Y, Reichardt B, et al. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Int J Clin Pharmacol Ther. 2012;50:867–872.
   PubMed Web of Science ®Google Scholar
• Yeaw J, Watson C, Fox KM, et al. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31:410–425.
   PubMed Web of Science ®Google Scholar
• González-López MA, Blanco R, González-Vela MC, et al. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817–820.
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10:159–169.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, McGonagle D, O’Connor P, et al. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis. 2003;62:74–76.
   PubMed Web of Science ®Google Scholar
• Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233–240.
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmüller U, Möller B, et al. The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatol Oxf Engl. 2007;46:93–96.
   PubMed Web of Science ®Google Scholar
• Schiotis R, Sánchez A, Escudero A, et al. Candidate’s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis. Rheumatol Int. 2014;34:793–801.
   PubMed Web of Science ®Google Scholar
• Chen -Y-Y. Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: a case-control study. Medicine (Baltimore). 2017;96:e5993.
   PubMed Web of Science ®Google Scholar
• Yan R-J, Lou -T-T, Wu Y-F, et al. Single nucleotide polymorphisms of ABCB1 gene and response to etanercept treatment in patients with ankylosing spondylitis in a Chinese Han population. Medicine (Baltimore). 2017;96:e5929.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen H, Wu G, et al. The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept. J Clin Lab Anal. 2017;23.
   Google Scholar
• Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol. 2008;28:445–455.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Krieckaert CLM, van der Kleij D, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis. 2015;74:1825–1829.
   PubMed Web of Science ®Google Scholar
• Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatol Oxf Engl. 2007;46:1338–1344.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Shin D, Kim Y, et al. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol. 2016;82:64–73.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51–57.
   PubMed Web of Science ®Google Scholar